Nanotechnology: A magic bullet for HIV AIDS treatment
Source abstract
Abstract
Human immunodeficiency virus (HIV) infection has become devastating in last a few years. Nearly 7400 new infection cases are coming every day. Highly active antiretroviral therapy (HAART), which involves combination of at least three antiretroviral (ARV) drugs, has been used to extend the life span of the HIV-infected patients. HAART has played an important role to reduce mortality rate in the developed countries but in the developing countries condition is still worst with millions of people being infected by this disease. For the improvement of the situation, nanotechnology-based drug system has been explored for the HIV therapeutics. Nanosystems used for HIV therapeutics offer some unique advantage like enhancement of bioavailability, water solubility, stability, and targeting ability of ARV drugs. Main nanotechnology-based systems explored for HIV therapeutics are liposomes, nanoparticles, niosomes, polymeric micelles, and dendrimers. Present manuscript reviews conventional method of HIV therapeutics and recent advances in the field of nanotechnology-based systems for treatment of HIV-AIDS.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Abdullah R · Afr J Biotechnol · 2011 · 10 · 1684
2. 10.1002/jps.1039710.1002/jps.10397 ↗
3. 10.1016/j.ejps.2010.10.00210.1016/j.ejps.2010.10.002 ↗
4. 10.4155/tde.10.9610.4155/tde.10.96 ↗
5. Alexaki A · Curr HIV Educ Res · 2008 · 6 · 38810.2174/157016208785861195 ↗
6. 10.3109/1061186090348339610.3109/10611860903483396 ↗
7. Amiji MM · Discov Med · 2006 · 6 · 157
8. Arendt CW · Genome Biol · 2001 · 2 · 103010.1186/gb-2001-2-11-reviews1030 ↗
9. 10.1021/nn800596w10.1021/nn800596w ↗
10. Asmal M · PLoS One · 2012 · 7 · 4823410.1371/journal.pone.0048234 ↗
11. Barbaro G · Curr Pharm Des · 2005 · 11 · 180510.2174/1381612053764869 ↗
12. 10.2165/00003088-199936040-0000410.2165/00003088-199936040-00004 ↗
13. 10.1021/ja710321g10.1021/ja710321g ↗
14. 10.1016/j.addr.2004.02.01410.1016/j.addr.2004.02.014 ↗
15. 10.1016/j.jconrel.2011.02.02310.1016/j.jconrel.2011.02.023 ↗
16. Canizal G · J Nanoparticle Res · 2001 · 3 · 47510.1023/A:1012578821566 ↗
17. 10.1038/nrd115110.1038/nrd1151 ↗
18. Chandraprakash KS · Drug Deliv · 1993 · 1 · 33310.3109/10717549309022767 ↗
19. 10.1007/s11095-008-9615-210.1007/s11095-008-9615-2 ↗
20. 10.1016/j.nano.2011.01.01710.1016/j.nano.2011.01.017 ↗
21. Chiappetta DA · Nanomedicine (Lond) · 2013 · 8 · 22310.2217/nnm.12.104 ↗
22. 10.2217/nnm.09.9010.2217/nnm.09.90 ↗
23. 10.1016/j.biomaterials.2010.11.08210.1016/j.biomaterials.2010.11.082 ↗
24. 10.1016/j.jaci.2007.06.00310.1016/j.jaci.2007.06.003 ↗
25. Clayton R · Antiviral Res · 2009 · 84 · 14210.1016/j.antiviral.2009.08.003 ↗
26. Clercq ED · Int J Antimicrob Agents · 2009 · 33 · 30710.1016/j.ijantimicag.2008.10.010 ↗
27. das Neves J · Mol Pharm · 2013 · 10 · 279310.1021/mp4002365 ↗
28. de Las Cuevas N · Curr Med Chem · 2012 · 19 · 505210.2174/0929867311209025052 ↗
29. 10.1093/jac/dkq31810.1093/jac/dkq318 ↗
30. Dubey V · J Drug Target · 2011 · 19 · 25810.3109/1061186X.2010.499460 ↗
31. 10.1016/j.ejps.2008.04.00210.1016/j.ejps.2008.04.002 ↗
32. 10.1080/1061186060096591410.1080/10611860600965914 ↗
33. 10.1186/1477-3155-3-610.1186/1477-3155-3-6 ↗
34. Florence AT, Bailie AJ. 1989. Non-ionic surfactant vesicles: alternatives to liposomes in drug delivery? In: Prescot LF, Nimmo WS, Eds. Novel Drug Delivery and Its Therapeutic Applications. Chichester: Wiley, Inc.; pp. 281–296.
35. 10.1016/S0005-2736(01)00432-110.1016/S0005-2736(01)00432-1 ↗
36. Gallo RC · Science · 1984 · 224 · 50010.1126/science.6200936 ↗
37. 10.1211/jpp.58.5.000510.1211/jpp.58.5.0005 ↗
38. 10.1016/j.ejpb.2006.12.01910.1016/j.ejpb.2006.12.019 ↗
39. 10.2165/00044011-200828060-0000510.2165/00044011-200828060-00005 ↗
40. 10.1021/bc049951i10.1021/bc049951i ↗
41. Gopinath D · Arzneimittelforschung · 2001 · 51 · 924
42. Hammer SM · JAMA · 2008 · 300 · 55510.1001/jama.300.5.555 ↗
43. Jaeghere FD · J Control Release · 2000 · 68 · 29110.1016/S0168-3659(00)00272-8 ↗
44. 10.2174/15672010677635922110.2174/156720106776359221 ↗
45. 10.2174/15672010878591507810.2174/156720108785915078 ↗
46. Jiménez JL · BioDrugs · 2010 · 24 · 33110.2165/11538400-000000000-00000 ↗
47. Jin SX · Pharmazie · 2005 · 60 · 840
48. Johnson VA · Top HIV Med · 2008 · 16 · 138
49. Kasongo KW · J Liposome Res · 2011 · 21 · 24510.3109/08982104.2010.539186 ↗
50. Kasongo KW · Pharm Dev Technol · 2012 · 17 · 35310.3109/10837450.2010.542163 ↗
51. Kasongo KW · J Pharm Sci · 2011 · 100 · 518510.1002/jps.22711 ↗
52. Kasongo KW · Drug Dev Ind Pharm · 2011 · 37 · 39610.3109/03639045.2010.516264 ↗
53. 10.1080/1061186080247568810.1080/10611860802475688 ↗
54. 10.1021/es900754q10.1021/es900754q ↗
55. 10.1172/JCI126910.1172/JCI1269 ↗
56. Kuo YC · Int J Pharm · 2006 · 327 · 16010.1016/j.ijpharm.2006.07.044 ↗
57. Kuo YC · Int J Pharm · 2009 · 365 · 206
58. 10.1016/j.ijpharm.2007.09.02010.1016/j.ijpharm.2007.09.020 ↗
59. 10.1016/j.ijpharm.2007.03.01210.1016/j.ijpharm.2007.03.012 ↗
60. 10.3109/1061186090349424510.3109/10611860903494245 ↗
61. 10.1016/j.colsurfb.2011.11.00710.1016/j.colsurfb.2011.11.007 ↗
62. 10.1016/j.colsurfb.2010.11.03710.1016/j.colsurfb.2010.11.037 ↗
63. 10.2217/nnm.11.2510.2217/nnm.11.25 ↗
64. Kuo YC · Colloids Surf B Biointerfaces · 2011 · 88 · 62710.1016/j.colsurfb.2011.07.053 ↗
65. 10.1016/j.ijpharm.2011.06.03710.1016/j.ijpharm.2011.06.037 ↗
66. 10.1016/j.ijpharm.2004.11.02510.1016/j.ijpharm.2004.11.025 ↗
67. Lanao JM · J Drug Target · 2007 · 15 · 2110.1080/10611860600942178 ↗
68. 10.1038/nrd70710.1038/nrd707 ↗
69. 10.1186/1477-3155-8-110.1186/1477-3155-8-1 ↗
70. Li Q · Eur J Pharm Sci · 2010 · 41 · 49810.1016/j.ejps.2010.08.004 ↗
71. 10.1021/mp800049w10.1021/mp800049w ↗
72. Lin JH · Adv Drug Del Rev · 1999 · 39 · 3310.1016/S0169-409X(99)00018-6 ↗
73. 10.1016/S0092-8674(00)81429-410.1016/S0092-8674(00)81429-4 ↗
74. Lu L · Antivir Ther · 2008 · 13 · 25310.1177/135965350801300210 ↗
75. Lucas S · Intensive Crit Care Nurs · 2000 · 17 · 15510.1054/iccn.2000.1541 ↗
76. Mainardes RM · J Nanosci Nanotechnol · 2012 · 12 · 851310.1166/jnn.2012.6638 ↗
77. Makabi-Panzu B · Cell Mol Biol (Noisy-le-grand) · 1998 · 44 · 277
78. Mallipeddi R · Int J Nanomed · 2010 · 5 · 53310.2217/nnm.10.25 ↗
79. Martins S · Int J Nanomed · 2007 · 2 · 595
80. 10.1016/S1474-4422(05)70165-410.1016/S1474-4422(05)70165-4 ↗
81. 10.1016/j.ejps.2011.06.00710.1016/j.ejps.2011.06.007 ↗
82. Mueller BU · Pediatrics · 1998 · 102 · 10110.1542/peds.102.1.101 ↗
83. 10.1021/bm015574q10.1021/bm015574q ↗
84. 10.1016/j.ejps.2012.10.02210.1016/j.ejps.2012.10.022 ↗
85. Neves JD · Adv Drug Del Rev · 2010 · 62 · 45810.1016/j.addr.2009.11.017 ↗
86. 10.1016/j.ejpb.2008.06.02010.1016/j.ejpb.2008.06.020 ↗
87. Ojikutu B · J Infect Dis · 2007 · 196 · S52310.1086/521119 ↗
88. Oussoren C · Int J Pharm · 1999 · 180 · 26110.1016/S0378-5173(99)00016-2 ↗
89. 10.1016/S0169-409X(02)00228-410.1016/S0169-409X(02)00228-4 ↗
90. Parthasarathy G · J Drug Target · 1994 · 2 · 17310.3109/10611869409015907 ↗
91. 10.1208/s12249-012-9871-710.1208/s12249-012-9871-7 ↗
92. 10.3109/02652048.2012.68050910.3109/02652048.2012.680509 ↗
93. Porcel E · Nanotechnology · 2010 · 21 · 8510.1088/0957-4484/21/8/085103 ↗
94. Poznansky M · Pharmacol Rev · 1984 · 36 · 27710.1016/S0031-6997(25)06651-7 ↗
95. 10.1016/j.jconrel.2013.05.02010.1016/j.jconrel.2013.05.020 ↗
96. 10.1016/j.ijpharm.2012.04.05410.1016/j.ijpharm.2012.04.054 ↗
97. 10.1186/1423-0127-17-5710.1186/1423-0127-17-57 ↗
98. 10.1248/yakushi.128.26910.1248/yakushi.128.269 ↗
99. 10.1126/science.116570610.1126/science.1165706 ↗
100. Ruckmani K · J Biomed Nanotechnol · 2010 · 6 · 4310.1166/jbn.2010.1101 ↗